NVO241213C115000
- 0.60
- -0.96-61.54%
Novo-Nordisk A/S Newsroom
Positive data from the FLOW renal outcomes trial has led to the updated labeling of semaglutide by Novo-Nordisk A/S being supported by the EMA.
In the FLOW trial, Ozempic significantly reduced the composite risk of progression of renal disease, cardiovascular events, and renal-related mortality by 24% compared to placebo.
Here's Why Novo Nordisk A/S (NVO) Fell in Q3
Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound
Novo Nordisk's Ozempic Gets EU Regulator Endorsement to Reduce Kidney Risks
European Medicines Agency's Committee For Medicinal Products For Human Use Adopted Positive Opinion For Update Of Novo Nordisk's Ozempic
Express News | Novo-Nordisk A/S: After the clinical trial results of the kidney therapy were released, the regulatory authorities in Europe gave a positive label evaluation to Ozempic.
Has Eli Lilly and Co's tirzepatide "defeated" Novo-Nordisk A/S's semaglutide? The competition for weight loss drugs is moving towards "precision breakthroughs."
Industry experts point out that the competition for weight loss drugs is no longer just about rapid weight loss, but requires a "targeted breakthrough" in safety and sustainability aspects, such as reducing weight regain, minimizing muscle loss, increasing medication convenience, and reducing side effects.
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $155
Xi'an Global Printing (002799.SZ): Has maintained a good cooperative relationship with Eli Lilly and Co and Novo-Nordisk A/S.
Gelonghui reported on December 12 that Xi'an Global Printing (002799.SZ) stated on the investor interaction platform that the company has maintained a good cooperative relationship with Eli Lilly and Co, Novo-Nordisk A/S, and other enterprises. In the future, the company will continue to strengthen market development efforts and expand its customer base.
Catalent Gains After Report Sale to Novo Holdings Could Close Soon
10 Health Care Stocks Whale Activity In Today's Session
Evotec And Novo Nordisk Launch First Projects For LAB EN2 Accelerator, Focusing On Cardiometabolic Diseases
Eli Lilly and Co (LLY.US) seeks to expand the indications for its weight loss medication and will conduct trials to treat addictive behaviors.
Eli Lilly and Co will test a weight loss drug for treating addiction in 2025.
BofA Restarts Coverage of 11 Large-cap Biopharmas
Novo Nordisk's Wegovy Sales Drop Is Temporary; Forecasts Still on Track -- Market Talk
Jim Cramer Is 'Not A Fan' Of Novavax, Says This Tech Stock Is 'Expensive'
Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate EKZ-102 Toward Clinical Development
Novo Nordisk Says Investment Aimed At Expanding Enzymes Output Used For The Production Of Insulin, GLP-1 Medicines
Novo Nordisk To Invest Additional 500M Reais To Expand Factory In Brazil
Novo Nordisk Just Got One Step Closer to Resolving Wegovy Supply Issue -- Barrons.com